Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer

Fig. 1

Frequency and distributions of peripheral blood Vδ2pos T cell subsets in patients affected by liver metastasis of colorectal cancer and underwent chemotherapy. a Representative dot plot flow cytometric graphs showing the gating strategy of viable CD45pos/CD3pos/Vδ2pos T lymphocytes. b Statistical dot plot graph showing the absolute number of CD3pos (left) and Vδ2pos (right) T cells per 1 mL of blood in healthy donors (n = 12; mean age: 49.3 ± 9.5) and CLM patients underwent CHT regimens (n = 16; mean age: 51.5 ± 8.1). c-e Representative dot plot graph flow cytometric graph (c) and pie charts (d and e) showing respectively the distribution and the percentages of CD27pos/CD45RApos TNaive (upper right in dot plot graph and light green in pie charts), CD27pos/CD45RAneg central memory (TCM) (upper left in dot plot graph and gray in pie charts), CD27neg/CD45RAneg effector-memory (TEM) (lower left in dot plot graph and purple in pie charts) and terminally-differentiated CD27neg/CD45RApos (TEMRA) (lower right in dot plot graph and orange in pie charts) Vδ2pos T cell subsets. Pie charts compare the frequencies of Vδ2pos T cell subsets between healthy donors (n = 34; mean age: 51.7 ± 10.8) with age-matched CLM patient underwent CHT (n = 33; mean age: 51.5 ± 8.1) d as well as between CLM patients naïve for CHT (n = 13; mean age: 69.5 ± 8.1) and age-matched CLM patients underwent CHT (n = 41; mean age: 70.1 ± 6.5) (e). f Statistical analysis showing the Pearson correlations between the frequency (%) of either TCM (left) or TEMRA (right) Vδ2pos T cells with the number of CHT cycles (mean number: 8.7 ± 6.5) administered to patients affected by CLM (n = 40)

Back to article page